CDTX

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 %

4 October 2025

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by

24 September 2025

Biotech · Drug Development · Investor Updates · NASDAQ:CDTX · Pharma News · Stock Market